New insights into osteoclastogenic signaling mechanisms

Trends in Endocrinology and Metabolism

Volumn 23, Issue 11, 2012, Pages 582-590

  Nakashima, Tomoki ^a,b   Hayashi, Mikihito ^a,b   Takayanagi, Hiroshi ^a,b,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

BONE DISEASE; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS; BONE REMODELING; BONE RESORPTION; FEMALE; HUMANS; IMMUNE SYSTEM; MALE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84867142035     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.05.005     Document Type: Review

References (85)

1. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007, 7:292-304.
2. Seeman E., Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 2006, 354:2250-2261.
3. Lorenzo J., et al. Osteoimmunology: interactions of the bone and immune system. Endocr. Rev. 2008, 29:403-440.
4. Rodan G.A., Martin T.J. Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif. Tissue Int. 1981, 33:349-351.
5. Burger E.H., et al. Osteoclast formation from mononuclear phagocytes: role of bone-forming cells. J. Cell Biol. 1984, 99:1901-1906.
6. Takahashi N., et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988, 123:2600-2602.
7. Suda T., et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999, 20:345-357.
8. Simonet W.S., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
9. Lacey D.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
10. Yasuda H., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3597-3602.
11. Anderson D.M., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
12. Wong B.R., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 1997, 272:25190-25194.
13. Tsuda E., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997, 234:137-142.
14. Kong Y.Y., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
15. Dougall W.C., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 13:2412-2424.
16. Li J., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1566-1571.
17. Mizuno A., et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J. Bone Miner. Metab. 2002, 20:337-344.
18. Bucay N., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
19. Mizuno A., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247:610-615.
20. Min H., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 2000, 192:463-474.
21. Nakashima T., Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J. Clin. Immunol. 2009, 29:555-567.
22. Nakashima T., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 2000, 275:768-775.
23. Hikita A., et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J. Biol. Chem. 2006, 281:36846-36855.
24. Miyamoto T., et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand. Blood 2000, 96:4335-4343.
25. Theill L.E., et al. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 2002, 20:795-823.
26. Bonewald L.F. The amazing osteocyte. J. Bone Miner. Res. 2011, 26:229-238.
27. Kamijou T., et al. Effects of osteocytes on osteoinduction in the autogenous rib graft in the rat mandible. Bone 1994, 15:629-637.
28. Shimizu H., et al. Bone resorption by isolated osteoclasts in living versus devitalized bone: differences in mode and extent and the effects of human recombinant tissue inhibitor of metalloproteinases. J. Bone Miner. Res. 1990, 5:411-418.
29. Corral D.A., et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13835-13840.
30. Galli C., et al. Commitment to the osteoblast lineage is not required for RANKL gene expression. J. Biol. Chem. 2009, 284:12654-12662.
31. Gu G., et al. Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res. 2006, 323:263-271.
32. Paic F., et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone 2009, 45:682-692.
33. Nakashima T., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 2011, 17:1231-1234.
34. Seeman E., Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 2006, 354:2250-2261.
35. Kramer I., et al. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol. 2010, 30:3071-3085.
36. Xiong J., et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 2011, 17:1235-1241.
37. Franz-Odendaal T.A., et al. Buried alive: how osteoblasts become osteocytes. Dev. Dyn. 2006, 235:176-190.
38. O'Brien C.A., et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008, 3:e2942.
39. Kim N., et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10905-10910.
40. Sobacchi C., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 2007, 39:960-962.
41. Lomaga M.A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999, 13:1015-1024.
42. Naito A., et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999, 4:353-362.
43. Wada T., et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat. Med. 2005, 11:394-399.
44. Bai S., et al. FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J. Clin. Invest. 2005, 115:2742-2751.
45. Franzoso G., et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 1997, 11:3482-3496.
46. Iotsova V., et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 1997, 3:1285-1289.
47. Wagner E.F., Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 2005, 208:126-140.
48. Sato K., et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat. Med. 2006, 12:1410-1416.
49. Takayanagi H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling for terminal differentiation of osteoclasts. Dev. Cell 2002, 3:889-901.
50. Crabtree G.R., Olson E.N. NFAT signaling: choreographing the social lives of cells. Cell 2002, 109(Suppl.):S67-S79.
51. Asagiri M., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 2005, 202:1261-1269.
52. Aliprantis A.O., et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J. Clin. Invest. 2008, 118:3775-3789.
53. Zhao B., et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 2009, 15:1066-1071.
54. Miyauchi Y., et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J. Exp. Med. 2010, 207:751-762.
55. Kim K., et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 2007, 109:3253-3259.
56. Nishikawa K., et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3117-3122.
57. Koga T., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
58. Barrow A.D., et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J. Clin. Invest. 2011, 121:3505-3516.
59. Zou W., et al. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. Mol. Cell 2008, 31:422-431.
60. Shinohara M., et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008, 132:794-806.
61. Bromley M., Woolley D.E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984, 27:968-975.
62. Gravallese E.M., et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 1998, 152:943-951.
63. Takayanagi H., et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997, 240:279-286.
64. Takayanagi H., et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000, 43:259-269.
65. Gravallese E.M., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43:250-258.
66. Kong Y.Y., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
67. Kadono Y., et al. Rheumatoid arthritis associated with osteopetrosis. Mod. Rheumatol. 2009, 19:687-690.
68. Pettit A.R., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 2001, 159:1689-1699.
69. Hikosaka Y., et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 2008, 29:438-450.
70. Akiyama T., et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008, 29:423-437.
71. Fata J.E., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
72. Loser K., et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 2006, 12:1372-1379.
73. - inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J. Exp. Med. 2007, 204:1267-1272.
74. hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J. Bone Miner. Res. 2004, 19:207-213.
75. Schramek D., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
76. Gonzalez-Suarez E., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
77. Kanzaki S., et al. Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin. Bone 2006, 39:414-419.
78. Guerrini M.M., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 2008, 83:64-76.
79. Hughes A.E., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 2000, 24:45-48.
80. Palenzuela L., et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. J. Med. Genet. 2002, 39:E67.
81. Whyte M.P., Hughes A.E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J. Bone Miner. Res. 2002, 17:26-29.
82. Gianfrancesco F., et al. A non-synonymous TNFRSF11A variation increases NFκB activity and the severity of Paget's disease. J. Bone Miner. Res. 2012, 27:443-452.
83. Whyte M.P., et al. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 2002, 347:175-184.
84. Cundy T., et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 2002, 11:2119-2127.
85. Chong B., et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J. Bone Miner. Res. 2003, 18:2095-2104.